Funded Research

Risk and outcomes of COVID-19 patients exposed to immunosuppressive and immunomodulatory agents in British Columbia. A population-based study.

Host institution

University of British Columbia

Research location

Arthritis Research Canada (ARC)

Partner

Supervisor

CO-lEad

To be better prepared for the second wave of COVID-19 in BC, we need to understand the risk factors influencing contracting the infection and its outcome in infected people, especially in vulnerable people, such as patients with auto-immune diseases, cancer or those with transplants who are being treated with immunosuppressive or immunomodulatory agents (IIA).

Patients using IIA for their care have raised fears about being at a greater risk of contracting COVID-19 as these medications lower the immune system. Also, they have uncertainties as IIA are being used to treat COVID-19.

In this study, we will assess: 

  1. The risk of COVID-19 infection among individuals who use IIA in BC,
  2. The risk of serious outcomes among COVID-19 patient who use IIA compared to patients who do not use IIA.

Building research careers

Since 2001, we’ve supported over 3,000 BC health researchers to launch programs, drive innovations, and attract millions in new research investment.

View all funded research

Funded research